Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.
Numinus Pilots Mental Health Program for Corporate Clients in Utah
Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.
Cybin Acquires DMT Clinical Study from Entheon Biomedical
Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.
Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation
Optimi Health announces the completion of its first crop of psilocybin mushrooms at the company's Princeton, B.C. cultivation facility.
Small Pharma Shares Business Update Ahead of Annual Financial Results
Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.